Design of an anti-CD160 mAb targeting CLL, HCL and immune cells for leukemia immunotherapy
The goal of the project is to develop a new monoclonal antibody (mAb) to treat B-Cell Chronic Lymphocytic Leukemia (CLL). The project partners will develop, produce, and validate a therapeutic mAb to simultaneously kill leukemia tumour cells and activate the antitumor immune response. This would be a major improvement in terms of efficacy and toxicity compared to current treatments. At the end of the project, the product will be ready to start regulatory and clinical development.
Cytology, Cancerology, Oncology
Drug delivery and other equipment (including kidney dialysis machines)